Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT)

Anticancer Research

Volumn 28, Issue 3 B, 2008, Pages 1767-1772

  Martelli, Olga ^a   Garassino, Marina ^b   Sacchetta, Sabrina ^c   Caristo, Rita ^c   Zivi, Andrea ^c   Cerbone, Linda ^c   Mancuso, Andrea ^c  

^a MOLINETTE HOSPITAL   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Anemia; Chemotherapy; Darbepoetin alfa; Supportive care

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEMCITABINE; HEMOGLOBIN; INTERFERON; IRINOTECAN; IRON; LETROZOLE; MITOXANTRONE; NAVELBINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLADDER CANCER; BLOOD TRANSFUSION; BREAST CANCER; CANCER PATIENT; CANCER STAGING; COLORECTAL CANCER; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH CANCER; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; TREATMENT RESPONSE; UTERUS CANCER;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PILOT PROJECTS; QUALITY OF LIFE;

EID: 45949083317     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Groopman JE and Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616-1634, 1999.
2. Littlewood TJ, Bajetta E, Nortier JW et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874, 2001.
3. Vansteenkiste J, Pirker R, Massuti B et al: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94: 1211-1220, 2002.
4. Steensma DP and Loprinzi CL: Epoetin alfa and darbepoetin alfa go head to head, J Clin Oncol 24(15): 2233-2236, 2006.
5. Glaspy J, ladeja JS, Justice G et al: A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer 84(suppl 1): 17-23, 2001.
6. Hedenus M, Hansen S, Taylor K et al: Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 119: 79-86, 2002.
7. Hedenus M, Adriansson M, San Miguel J et al: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122: 394-403, 2003.
8. Glaspy J, Henry D, Patel R et al: Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 41: 1140-1149, 2005.
9. Kotasek D, Steger G, Faught W et al: Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 39: 2026-2034, 2003.
10. Glaspy J: Phase III clinical trials with darbepoetin: implications for clinicians. Best Pract Res Clin Haematol 18: 407-416, 2005.
11. Hesketh PJ, Arena F, Patel D et al: A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer 100: 859-868, 2004.
12. Justice G, Kessler JF, Jadeja J et al: A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia. Ann Oncol 16: 1192-1198, 2005.
13. Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B and Silberstein P: Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist 11(4): 409-417, 2006.
14. Glaspy J: Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia, Oncology (Williston Park) 20(8 Suppl 6): 29-32, 2006.
15. Heatherington AC, Schuller J, Mercer AJ et al: The pharmacokinetics of darbepoetin alfa administered subcutaneously in patients with non-myeloid malignancies receiving multicycle chemotherapy. Blood 98: 298a, 2001.